Drugs / CDX-301
CDX-301
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05029999 | Apr 2022 → Apr 2028 expected | Her2-receptor negative breast cancer | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05010200 | Jan 2022 → Jan 2027 expected | prostate cancer | Ashutosh Kumar Tewari | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04930783 | Jan 2022 → Dec 2027 expected | melanoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03835533 | Jun 2019 → Oct 2022 | prostate carcinoma | Parker Institute for Cancer Immunotherapy | Completed | No outcome recorded |
| Phase 1 | NCT01465139 | Oct 2011 → Nov 2012 | — | Celldex Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04491084 | Jan 2021 → Aug 2022 | non-small cell lung carcinoma | Albert Einstein College of Medicine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 25 trials | ||||||
| Phase 2 | NCT04536077 | Aug 2021 → Nov 2023 | malignant pancreatic neoplasm | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT02839265 | Jul 2016 → Oct 2022 | non-small cell lung carcinoma | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02302339 | Nov 2014 → Jun 2018 | melanoma | Celldex Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT02200380 | Jul 2014 → Mar 2016 | B-cell chronic lymphocytic leukemia, Hodgkins lymphoma, acute myeloid leukemia, chronic myeloid leukemia +1 | Celldex Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT02129075 | Apr 2014 → Mar 2016 | cutaneous melanoma, mucosal melanoma, ocular melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT03329950 Background | Dec 2017 → Sep 2022 | MALT lymphoma, Waldenstrom macroglobulinemia, breast cancer, cholangiocarcinoma +16 | Celldex Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT03804944 Comparator | Mar 2020 → Dec 2026 expected | breast cancer | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-11-09 | Celldex Therapeutics | Results Celldex Presents Data from Oncology Portfolio at SITC 2020 celldex.com ↗
Pre-treatment of patients with CDX-301 greatly increased the number of circulating dendritic cells prior to CDX-1140 administration and peripheral blood mononuclear cells (PBMCs) isolated from CDX-301 pretreated patients were more responsive to CDX-1140 than PBMCs from non-pretreated patients. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-11-09 | Celldex Therapeutics | Celldex Presents Data from Oncology Portfolio at SITC 2020 celldex.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CDX-301 | “regimen of Flt3L (CDX-301) to increase DCs and other antigen-presenting cells” PMID 35121932 ↗ Nov 2020 |
| Known as | FLT3 Ligand | “FLT3 Ligand (CDX-301)” NCT04491084 ↗ |
| Known as | FLT3L | “FLT3L (CDX-301, the recombinant human protein by Celldex)” NCT03804944 ↗ |
| Known as | rhuFlt3L | “CDX-301 (rhuFlt3L) With or Without Plerixafor for the Mobilization and Transplantation of Allogeneic Blood Cell Grafts in HLA-Matched Donor/Recipient Sibling Pairs” NCT02200380 ↗1“CDX-301 (rhuFlt3L)” NCT01465139 ↗ |
| Modality | Protein / enzyme biologic | “CDX-301 is a protein that stimulates the growth of bone marrow stem cells and certain immune cells.” NCT01465139 ↗ |
| Route | Subcutaneous | “Given SC” NCT02129075 ↗ |